These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 37737075)

  • 21. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria.
    Ouderkirk JP; Nord JA; Turett GS; Kislak JW
    Antimicrob Agents Chemother; 2003 Aug; 47(8):2659-62. PubMed ID: 12878536
    [TBL] [Abstract][Full Text] [Related]  

  • 22. To B or not to B, that is the question: is it time to replace colistin with polymyxin B?
    Kassamali Z; Danziger L
    Pharmacotherapy; 2015 Jan; 35(1):17-21. PubMed ID: 25346395
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nephrotoxicity prevalence in patients treated with polymyxins: a systematic review with meta-analysis of observational studies.
    Oliota AF; Penteado ST; Tonin FS; Fernandez-Llimos F; Sanches AC
    Diagn Microbiol Infect Dis; 2019 May; 94(1):41-49. PubMed ID: 30635223
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study.
    Rigatto MH; Behle TF; Falci DR; Freitas T; Lopes NT; Nunes M; Costa LW; Zavascki AP
    J Antimicrob Chemother; 2015 May; 70(5):1552-7. PubMed ID: 25604744
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Comparison of Adjusted Versus Unadjusted Doses of Polymyxin B Based on Renal Function and Incidence of Acute Kidney Injury.
    Peyko V; Cohen H
    J Pharm Pract; 2020 Jun; 33(3):255-261. PubMed ID: 30189762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of Renal Toxicity of Colistin Therapy With Neutrophil Gelatinase-associated Lipocalin: a Biomarker of Renal Tubular Damage.
    Ordooei Javan A; Salamzadeh J; Shokouhi S; Sahraei Z
    Iran J Kidney Dis; 2017 Nov; 11(6):447-455. PubMed ID: 29190605
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimal Empiric Polymyxin B Treatment of Patients Infected with Gram-Negative Organisms Detected Using a Blood Antimicrobial Surveillance Network in China.
    Wu X; Huang C; Wang H; Ji J; Ying C; Xiao Y
    Drug Des Devel Ther; 2021; 15():2593-2603. PubMed ID: 34168431
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incidence of nephrotoxicity associated with intravenous colistimethate sodium administration for the treatment of multidrug-resistant gram-negative bacterial infections.
    Sadyrbaeva-Dolgova S; García-Fumero R; Exposito-Ruiz M; Pasquau-Liaño J; Jiménez-Morales A; Hidalgo-Tenorio C
    Sci Rep; 2022 Sep; 12(1):15261. PubMed ID: 36088407
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polymyxin-induced nephrotoxicity and its predictors: a systematic review and meta-analysis of studies conducted using RIFLE criteria of acute kidney injury.
    Sisay M; Hagos B; Edessa D; Tadiwos Y; Mekuria AN
    Pharmacol Res; 2021 Jan; 163():105328. PubMed ID: 33276108
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Greater optimisation of pharmacokinetic/pharmacodynamic parameters through a loading dose of intravenous colistin in paediatric patients.
    Wacharachaisurapol N; Phasomsap C; Sukkummee W; Phaisal W; Chanakul A; Wittayalertpanya S; Chariyavilaskul P; Puthanakit T
    Int J Antimicrob Agents; 2020 Jun; 55(6):105940. PubMed ID: 32179149
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical use of intravenous polymyxin B for the treatment of patients with multidrug-resistant Gram-negative bacterial infections: An evaluation of the current evidence.
    Falagas ME; Kyriakidou M; Voulgaris GL; Vokos F; Politi S; Kechagias KS
    J Glob Antimicrob Resist; 2021 Mar; 24():342-359. PubMed ID: 33486122
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Battle of polymyxin induced nephrotoxicity: Polymyxin B versus colistin.
    Ballı FN; Ekinci PB; Kurtaran M; Kara E; Dizman GT; Sönmezer MÇ; Hayran M; Demirkan K; Metan G
    Int J Antimicrob Agents; 2024 Feb; 63(2):107035. PubMed ID: 37979889
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nephrotoxicity of intravenous colistin: a prospective evaluation.
    Falagas ME; Fragoulis KN; Kasiakou SK; Sermaidis GJ; Michalopoulos A
    Int J Antimicrob Agents; 2005 Dec; 26(6):504-7. PubMed ID: 16280245
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of colistin in critically ill patients with multidrug-resistant Gram-negative bacilli infection.
    Karnik ND; Sridharan K; Jadhav SP; Kadam PP; Naidu RK; Namjoshi RD; Gupta V; Gore MS; Surase PV; Mehta PR; Gogtay JA; Thatte UM; Gogtay NJ
    Eur J Clin Pharmacol; 2013 Jul; 69(7):1429-36. PubMed ID: 23508665
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of heme oxygenase-1 in polymyxin B-induced nephrotoxicity in rats.
    Dezoti Fonseca C; Watanabe M; Vattimo Mde F
    Antimicrob Agents Chemother; 2012 Oct; 56(10):5082-7. PubMed ID: 22802257
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Colistin Population Pharmacokinetics after Application of a Loading Dose of 9 MU Colistin Methanesulfonate in Critically Ill Patients.
    Karaiskos I; Friberg LE; Pontikis K; Ioannidis K; Tsagkari V; Galani L; Kostakou E; Baziaka F; Paskalis C; Koutsoukou A; Giamarellou H
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7240-8. PubMed ID: 26369974
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of low-dose colistin in the treatment for infections caused by multidrug-resistant gram-negative bacteria.
    Zaidi ST; Al Omran S; Al Aithan AS; Al Sultan M
    J Clin Pharm Ther; 2014 Jun; 39(3):272-6. PubMed ID: 24593154
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of polymyxin-B-associated acute kidney injury in 1-year mortality and renal function recovery.
    Gomes EC; Falci DR; Bergo P; Zavascki AP; Rigatto MH
    Int J Antimicrob Agents; 2018 Jul; 52(1):86-89. PubMed ID: 29501603
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of nephrotoxicity and prognosis in patients treated with colistin due to hospital-acquired pneumonia.
    Korkmaz Ekren P; Töreyin ZN; Berk Takır H; Kalamanoğlu Balcı M; Gaygısız Ü; Gürsel G; Ergan B; Yalçın A; Saltürk C; Aydoğdu M; Ergün R; Güven P; Ulubay G; Gürün Kaya A; Çeltik A; Uluer H; Bacakoğlu F; Sayıner A
    Tuberk Toraks; 2017 Dec; 65(4):271-281. PubMed ID: 29631525
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Parenteral polymyxin B use in patients with multidrug-resistant gram-negative bacteremia and urinary tract infections: a retrospective case series.
    Pastewski AA; Caruso P; Parris AR; Dizon R; Kopec R; Sharma S; Mayer S; Ghitan M; Chapnick EK
    Ann Pharmacother; 2008 Sep; 42(9):1177-87. PubMed ID: 18664609
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.